Inhibitors of acyl-CoA:cholesterol acyltransferase. 1. Identification and structure-activity relationships of a novel series of fatty acid anilide hypocholesterolemic agents

• Published in: Journal of medicinal chemistry Vol. 35; no. 9; pp. 1609 - 1617
• Main Authors: Roth, Bruce D, Blankley, C. John, Hoefle, Milton L, Holmes, Ann, Roark, W. Howard, Trivedi, Bharat K, Essenburg, Arnold D, Kieft, Karen A, Krause, Brian R, Stanfield, Richard L
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 01.05.1992
• Subjects: Animals; Cholesterol - blood; Cholesterol, Dietary - administration & dosage; Hypolipidemic Agents - pharmacology; Male; Rabbits; Rats; Rats, Inbred Strains; Sterol O-Acyltransferase - antagonists & inhibitors; Structure-Activity Relationship
• ISSN: 0022-2623; 1520-4804
• DOI: 10.1021/jm00087a016

A series of fatty acid anilides was prepared, and compounds were tested for their ability to inhibit the enzyme acyl-CoA:cholesterol acyltransferase (ACAT) in vitro and to lower plasma total cholesterol and elevate high-density lipoprotein cholesterol in cholesterol-fed rats in vivo. The compounds reported were found to fall into two subclasses with different anilide SAR. For nonbranched acyl analogues, inhibitory potency was found to be optimal with bulky 2,6-dialkyl substitution. For alpha-substituted acyl analogues, there was little dependence of in vitro potency on anilide substitution and 2,4,6-trimethoxy was uniquely preferred. Most of the potent inhibitors (IC50 less than 50 nM) were found to produce significant reductions in plasma total cholesterol in cholesterol-fed rats. Additionally, in vivo activity could be improved significantly by the introduction of alpha,alpha-disubstitution into the fatty acid portion of the molecule. A narrow group of alpha,alpha-disubstituted trimethoxyanilides, exemplified by 2,2-dimethyl-N-(2,4,6-trimethoxyphenyl)dodecanamide (39), was found to not only lower plasma total cholesterol (-60%) in cholesterol-fed rats but also elevate levels of high-density lipoprotein cholesterol (+94%) in this model at the screening dose of 0.05% in the diet (ca. 50 mg/kg).